report revenu y/i constant currenc cc
driven strength core breast health busi cc intern sale
cc ex cynosur cyno vs estimate street
organ basi total sale increas y/i exclud blood screen
cyno organ vs flat estimate cyno improv revenu ahead
estimate q/q growth said cyno still face near-term
challeng exemplifi recent fda letter compani market laser
ultim benefit given advanc clinic program
peer gross margin declin y/i oper margin declin
y/i due geograph product mix non-gaap ep
ahead street estimate lower share count tax rate ad
cfo transit tuck deal buy-back
along result also announc cfo bob mcmahon leav
compani becom cfo agil buy karleen oberton current holx chief
account offic compani year promot
cfo addit acquir faxitron bioptic privat compani product
digit specimen radiographi breast lesion local sentinel lymph node biopsi
complement intervent breast solut busi
mani move part mani posit view exclud blood
screen see organ growth improv cc
reiter buy rate share
guid updat rais est increas po
rais revenu guid midpoint kept
midpoint ep guid rais sale ep est
ep respect higher est po
increas still base ep estimate yr averag
net dbt
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
lead manufactur medic
devic product focus heathcar need
mammographi breast biopsi earli stage
treatment remov uterin fibroid
compani acquir cynosur lead
medic aesthet compani larg portfolio
laser-bas product
core mammographi
diagnost busi perform better
expect especi ou market help
off-set concern surpris cynosur
acquisit done hide slow growth
continu reserv
cynosur believ expect like
bottom point call
option view better expect result
cynosur could help close valuat gap
dx peer
po base approxim calendar ep estim impli
ev/ebitda in-line three-year histor averag
discount compani dx/medtech peer multipl
upsid risk po better-than-expect synergi cynosur
acquisit unreal benefit chang tax code faster growth
core diagnost mammographi gynecolog surgeri end market
ynosur competit pressur slower uptak reimburs new product
unfavor chang clinic practic guidelin manag departur regulatori
risk faster declin legaci busi
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
